Joseph Schwartz
Stock Analyst at Leerink Partners
(4.94)
# 164
Out of 4,634 analysts
1311
Total ratings
54.3%
Success rate
32.8%
Average return
Main Sectors:
Stocks Rated by Joseph Schwartz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GOSS Gossamer Bio | Upgraded: Buy | $6 → $1 | $0.1761 | +467.86% | 36 | Jul 27, 2026 | |
| QNCX Quince Therapeutics | Initiated Coverage: Buy | $80 | $30.65 | +161.01% | 1 | Jun 24, 2026 | |
| QURE uniQure | Reiterated: Buy | $60 → $70 | $46.06 | +51.98% | 62 | Jun 17, 2026 | |
| EWTX Edgewise Therapeutics | Reiterated: Buy | $52 | $44.58 | +16.64% | 50 | Jun 16, 2026 | |
| CRNX Crinetics Pharmaceuticals | Maintained: Buy | $88 → $95 | $84.15 | +12.89% | 46 | Jun 11, 2026 | |
| ASND Ascendis Pharma | Reiterated: Buy | $225 → $305 | $255.62 | +19.32% | 72 | Jun 2, 2026 | |
| FULC Fulcrum Therapeutics | Downgraded: Hold | $24 → $4 | $3.75 | +6.67% | 37 | Jun 2, 2026 | |
| BMRN BioMarin Pharmaceutical | Reiterated: Hold | $60 → $62 | $68.88 | -9.99% | 90 | May 18, 2026 | |
| SPRB Spruce Biosciences | Reiterated: Buy | $160 → $120 | $46.20 | +159.74% | 32 | May 15, 2026 | |
| ANTX AN2 Therapeutics | Upgraded: Buy | $1 → $9 | $5.91 | +52.28% | 23 | May 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $25 | $12.24 | +104.25% | 1 | May 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $27.91 | $13.85 | +101.48% | 1 | Apr 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $26 → $25 | $6.07 | +311.86% | 31 | Mar 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $15 | $17.18 | -12.69% | 107 | Mar 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $50 | $27.28 | +83.28% | 9 | Mar 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $60.89 | - | 87 | Jan 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $26.80 | - | 69 | Jan 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $38 | $34.84 | +9.07% | 37 | Jan 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $1.96 | - | 50 | Dec 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 → $2 | $0.2724 | +634.21% | 31 | Dec 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $20 | $8.56 | +133.64% | 45 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $12 → $16 | $15.45 | +3.56% | 52 | Dec 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $5 → $14 | $14.33 | -2.30% | 29 | Dec 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $115 | $116.35 | -1.16% | 1 | Nov 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $54 | $74.63 | -27.64% | 33 | Oct 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $134.75 | - | 63 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $25 | $4.01 | +523.44% | 22 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $10 | $2.99 | n/a | 29 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $1 | $1.21 | n/a | 29 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $10 | $4.06 | n/a | 19 | May 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $14 | $277.00 | n/a | 1 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $150 → $30 | $8.76 | n/a | 10 | Aug 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $40 → $34 | $56.94 | n/a | 3 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $30 | $150.00 | n/a | 28 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $417.20 | n/a | 1 | Aug 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $7.99 | n/a | 1 | Jul 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $31 → $4 | $59.42 | n/a | 16 | Apr 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Sell | n/a | $359.79 | n/a | 1 | May 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $53.02 | $231.82 | n/a | 1 | Apr 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $5 → $30 | $1.04 | n/a | 2 | Jan 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $37 → $23 | $12.02 | n/a | 2 | Nov 28, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $10 → $12 | $1.81 | n/a | 5 | Sep 26, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $121 → $126 | $529.66 | n/a | 4 | Apr 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $14.26 | n/a | 11 | Nov 13, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 | $0.06305 | n/a | 5 | Nov 10, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $12 → $14 | $5.00 | n/a | 6 | Nov 10, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $24 | $0.7311 | n/a | 1 | Mar 8, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $664 | $808.05 | n/a | 7 | Oct 26, 2015 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $512 → $425 | $207.13 | n/a | 3 | Sep 15, 2015 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $20 → $8 | $77.49 | n/a | 3 | May 19, 2014 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $14.11 | n/a | 6 | Oct 30, 2013 |
Gossamer Bio
Jul 27, 2026
Upgraded: Buy
Price Target: $6 → $1
Current: $0.1761
Upside: +467.86%
Quince Therapeutics
Jun 24, 2026
Initiated Coverage: Buy
Price Target: $80
Current: $30.65
Upside: +161.01%
uniQure
Jun 17, 2026
Reiterated: Buy
Price Target: $60 → $70
Current: $46.06
Upside: +51.98%
Edgewise Therapeutics
Jun 16, 2026
Reiterated: Buy
Price Target: $52
Current: $44.58
Upside: +16.64%
Crinetics Pharmaceuticals
Jun 11, 2026
Maintained: Buy
Price Target: $88 → $95
Current: $84.15
Upside: +12.89%
Ascendis Pharma
Jun 2, 2026
Reiterated: Buy
Price Target: $225 → $305
Current: $255.62
Upside: +19.32%
Fulcrum Therapeutics
Jun 2, 2026
Downgraded: Hold
Price Target: $24 → $4
Current: $3.75
Upside: +6.67%
BioMarin Pharmaceutical
May 18, 2026
Reiterated: Hold
Price Target: $60 → $62
Current: $68.88
Upside: -9.99%
Spruce Biosciences
May 15, 2026
Reiterated: Buy
Price Target: $160 → $120
Current: $46.20
Upside: +159.74%
AN2 Therapeutics
May 15, 2026
Upgraded: Buy
Price Target: $1 → $9
Current: $5.91
Upside: +52.28%
May 15, 2026
Initiated Coverage: Buy
Price Target: $25
Current: $12.24
Upside: +104.25%
Apr 6, 2026
Initiated Coverage: Buy
Price Target: $27.91
Current: $13.85
Upside: +101.48%
Mar 26, 2026
Reiterated: Buy
Price Target: $26 → $25
Current: $6.07
Upside: +311.86%
Mar 25, 2026
Maintained: Hold
Price Target: $15
Current: $17.18
Upside: -12.69%
Mar 25, 2026
Reiterated: Buy
Price Target: $50
Current: $27.28
Upside: +83.28%
Jan 13, 2026
Maintained: Buy
Price Target: n/a
Current: $60.89
Upside: -
Jan 13, 2026
Reiterated: Buy
Price Target: n/a
Current: $26.80
Upside: -
Jan 13, 2026
Reiterated: Buy
Price Target: $38
Current: $34.84
Upside: +9.07%
Dec 31, 2025
Reiterated: Hold
Price Target: n/a
Current: $1.96
Upside: -
Dec 29, 2025
Reiterated: Buy
Price Target: $8 → $2
Current: $0.2724
Upside: +634.21%
Dec 15, 2025
Reiterated: Buy
Price Target: $20
Current: $8.56
Upside: +133.64%
Dec 3, 2025
Downgraded: Hold
Price Target: $12 → $16
Current: $15.45
Upside: +3.56%
Dec 3, 2025
Upgraded: Buy
Price Target: $5 → $14
Current: $14.33
Upside: -2.30%
Nov 10, 2025
Initiated Coverage: Buy
Price Target: $115
Current: $116.35
Upside: -1.16%
Oct 16, 2025
Reiterated: Hold
Price Target: $54
Current: $74.63
Upside: -27.64%
Sep 29, 2025
Reiterated: Buy
Price Target: n/a
Current: $134.75
Upside: -
Aug 15, 2025
Reiterated: Buy
Price Target: $25
Current: $4.01
Upside: +523.44%
Aug 7, 2025
Maintained: Buy
Price Target: $10
Current: $2.99
Upside: n/a
Aug 12, 2024
Reiterated: Hold
Price Target: $1
Current: $1.21
Upside: n/a
May 7, 2024
Reiterated: Hold
Price Target: $10
Current: $4.06
Upside: n/a
Sep 7, 2023
Maintained: Hold
Price Target: $14
Current: $277.00
Upside: n/a
Aug 18, 2023
Downgraded: Hold
Price Target: $150 → $30
Current: $8.76
Upside: n/a
Feb 3, 2023
Maintained: Hold
Price Target: $40 → $34
Current: $56.94
Upside: n/a
Aug 5, 2022
Reiterated: Buy
Price Target: $30
Current: $150.00
Upside: n/a
Aug 4, 2022
Rated: Hold
Price Target: n/a
Current: $417.20
Upside: n/a
Jul 13, 2022
Maintained: Buy
Price Target: n/a
Current: $7.99
Upside: n/a
Apr 5, 2022
Downgraded: Hold
Price Target: $31 → $4
Current: $59.42
Upside: n/a
May 7, 2021
Downgraded: Sell
Price Target: n/a
Current: $359.79
Upside: n/a
Apr 15, 2021
Maintained: Buy
Price Target: $53.02
Current: $231.82
Upside: n/a
Jan 6, 2021
Downgraded: Hold
Price Target: $5 → $30
Current: $1.04
Upside: n/a
Nov 28, 2018
Initiated Coverage: Buy
Price Target: $37 → $23
Current: $12.02
Upside: n/a
Sep 26, 2017
Maintained: Buy
Price Target: $10 → $12
Current: $1.81
Upside: n/a
Apr 3, 2017
Maintained: Hold
Price Target: $121 → $126
Current: $529.66
Upside: n/a
Nov 13, 2016
Reiterated: Buy
Price Target: n/a
Current: $14.26
Upside: n/a
Nov 10, 2016
Reiterated: Buy
Price Target: $8
Current: $0.06305
Upside: n/a
Nov 10, 2016
Reiterated: Buy
Price Target: $12 → $14
Current: $5.00
Upside: n/a
Mar 8, 2016
Maintained: Buy
Price Target: $24
Current: $0.7311
Upside: n/a
Oct 26, 2015
Reiterated: Buy
Price Target: $664
Current: $808.05
Upside: n/a
Sep 15, 2015
Maintained: Buy
Price Target: $512 → $425
Current: $207.13
Upside: n/a
May 19, 2014
Initiated Coverage: Buy
Price Target: $20 → $8
Current: $77.49
Upside: n/a
Oct 30, 2013
Downgraded: Hold
Price Target: n/a
Current: $14.11
Upside: n/a